BC
Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
$22.64 -0.53% (-$0.12)
1M -3.99%
Market Cap $1.48B
P/E Ratio -
Div. Yield -
ROE 41.49%
Piotroski F-Score Weak
1/9Valuation
64 /100
Fair P/B 3.17x
EV/EBITDA N/A
P/S N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 41.49%
ROA 36.19%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 11.59x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
39 /100
Moderate EPS volatility 41.20%
Profitable years 0
Beta -0.82x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o BCAX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Claire Mazumdar Clemon
Employees
103
Headquarters
Boston
Prihajajoči dogodki
09 NOV.
Earnings
Upcoming earnings report